FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0104							
Estimated average burden								
hours per response:	0.5							

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* RedCo II Master Fund, L.P.		2. Date of Event R Statement (Month, 05/02/2023		3. Issuer Name and Ticker or Trading Symbol Augmedix, Inc. [AUGX]								
(Last) C/O REDMILE ONE LETTER D3-300 (Street) SAN FRANCISCO (City)	(First) GROUP, LLC MAN DRIVE, BI CA (State)	(Middle) LDG D SUITE 94129 (Zip)				onship of Reporting Pe all applicable) Director Officer (give title below)	X	to Issuer 10% Owner Other (specif below)	(N 6.	•		
Table I - Non-Derivative Securities Beneficially Owned												
1. Title of Security (Instr. 4)						t of Securities ly Owned (Instr. 4)	- [1			Nature of Indirect Beneficial Ownership (Instr. 5)		
Common Stock						8,696,146		D ⁽¹⁾				
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)												
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable at Expiration Date (Month/Day/Year)			ate	d 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)			4. Conversion	e (D) or	6. Nature of Indirect Beneficial Ownership (Instr. 5)			
		Date Exercisable	Expiration Date	Title			Amount or Number of Shares	Price of Derivative Security	Indirect (I) (Instr. 5)			
Pre-Funded Warrants to Purchase Common Stock			04/19/2023(2)	(2)		Common Stock		3,125,195	0.0001(2	D(3)		

Explanation of Responses:

- 1. Redmile Group, LLC ("Redmile") has filed a Form 4 concurrently with RedCo II Master Fund, L.P.'s ("RedCo II") filing of this Form 3 to report Redmile's indirect beneficial ownership of the Common Stock.
- 2. The Pre-Funded Warrants are exercisable by the holder at any time on or after the date of the securities purchase agreement between Augmedix, Inc. (the "Issuer") and certain stockholders, including RedCo II Master Fund, L.P., dated as of April 19, 2023, until fully exercised at an exercise price of \$0.0001 per Pre-Funded Warrant share, subject to a limitation on the right of the Issuer to issue the Pre-Funded Warrant shares if and to the extent that such exercise would violate the rules or regulations of Nasdaq Stock Market LLC. The Pre-Funded Warrants have no expiration date.
- 3. Redmile filed a Form 4 on April 21, 2023 to report its indirect beneficial ownership of the Pre-Funded Warrants.

Remarks:

Rob Faulkner, a member of the board of directors of the Issuer and a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile and its affiliates. As a result, the Reporting Person is a director by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

/s/ Jeremy Green, Managing
Member of RedCo II (GP), LLC,
general partner of RedCo II Master
Fund, L.P.

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.